Table 1.
Statistics of period and amplitude of the oscillation of MOG-specific T cells and microglia in EAE
| Period (days) | Amplitude (%) | Period (days) | Amplitude (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
EAE |
Spleen |
MOG-Teff |
5 ± 0.7 |
0.8 ± 0.2 * |
EAE anti-CD20 therapy |
Spleen |
MOG-Teff |
6.7 ± 0.7 |
0.3 ± 0.1 * |
|
MOG-Treg |
4.3 ± 0.9 |
0.14 ± 0.02 * |
MOG-Treg |
6.7 ± 2.7 |
0.06 ± 0.02 * |
||||
|
CNS |
MOG-Teff |
4 ± 1 |
3.3 ± 0.9 |
CNS |
MOG-Teff |
3.0 ± 0.4 |
2.4 ± 1.4 |
||
|
MOG-Treg |
2.3 ± 0.9 |
4.0 ± 0.9 *** |
MOG-Treg |
3.3 ± 0.7 |
0.5 ± 0.2 *** |
||||
|
Microglia (activated) |
8 |
60 ± 7 |
Microglia (activated) |
-- |
57 ± 9 |
||||
| |
|
|
Period (days) |
Amplitude (cell num) |
|
|
|
Period (days) |
Amplitude (cell num) |
| Model EAE | Spleen |
MOG-Teff |
5.2 ± 0.2 * |
2254 ± 128 *** |
Model EAE anti-CD20 therapy | Spleen |
MOG-Teff |
6.5 ± 0.5 * |
816 ± 18 *** |
| MOG-Treg | 4.9 ± 0.2 | 552 ± 26 *** | MOG-Treg | 5.5 ± 0.4 | 429 ± 10 *** |
Period and amplitude of the peaks of active MOG-Teff , MOG-Treg and activated microglia in secondary lymphoid organs (spleen) and the CNS in animals developing EAE (as described in Figure 2), in model simulations (as described in Figure 4) and animals with EAE and treated with anti-CD20 therapy (as described in Figure 6). Amplitudes of MOG-specific T cells and activated microglia are shown as percentages to the CD4+ population and total microglia population, respectively; amplitudes in model simulations are expressed as cell number values. Data is shown as the mean ± SEM, statistical significance are between EAE versus EAE anti-CD20 therapy; sig. (*) p < 0.05, (***) p < 0.0001 (paired T test).